CRNX
Price
$31.26
Change
+$1.11 (+3.68%)
Updated
Apr 22, 04:59 PM (EDT)
Capitalization
2.81B
16 days until earnings call
KRYS
Price
$168.60
Change
+$6.69 (+4.13%)
Updated
Apr 22, 04:59 PM (EDT)
Capitalization
4.68B
14 days until earnings call
Ad is loading...

CRNX vs KRYS

Header iconCRNX vs KRYS Comparison
Open Charts CRNX vs KRYSBanner chart's image
Crinetics Pharmaceuticals
Price$31.26
Change+$1.11 (+3.68%)
Volume$8.52K
Capitalization2.81B
Krystal Biotech
Price$168.60
Change+$6.69 (+4.13%)
Volume$3.88K
Capitalization4.68B
CRNX vs KRYS Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. KRYS commentary
Apr 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and KRYS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 22, 2025
Stock price -- (CRNX: $30.15 vs. KRYS: $161.91)
Brand notoriety: CRNX and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 61% vs. KRYS: 91%
Market capitalization -- CRNX: $2.81B vs. KRYS: $4.68B
CRNX [@Biotechnology] is valued at $2.81B. KRYS’s [@Biotechnology] market capitalization is $4.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $285.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while KRYS’s TA Score has 5 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 3 bearish.
  • KRYS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than KRYS.

Price Growth

CRNX (@Biotechnology) experienced а +1.24% price change this week, while KRYS (@Biotechnology) price change was -4.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.69%. For the same industry, the average monthly price growth was -9.18%, and the average quarterly price growth was -11.79%.

Reported Earning Dates

CRNX is expected to report earnings on Aug 08, 2025.

KRYS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+5.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.68B) has a higher market cap than CRNX($2.81B). KRYS YTD gains are higher at: 3.351 vs. CRNX (-41.033). KRYS has higher annual earnings (EBITDA): 110M vs. CRNX (-336.07M). CRNX has more cash in the bank: 1.35B vs. KRYS (598M). KRYS has less debt than CRNX: KRYS (7.26M) vs CRNX (51.7M). KRYS has higher revenues than CRNX: KRYS (291M) vs CRNX (1.04M).
CRNXKRYSCRNX / KRYS
Capitalization2.81B4.68B60%
EBITDA-336.07M110M-306%
Gain YTD-41.0333.351-1,224%
P/E RatioN/A53.97-
Revenue1.04M291M0%
Total Cash1.35B598M226%
Total Debt51.7M7.26M712%
FUNDAMENTALS RATINGS
CRNX vs KRYS: Fundamental Ratings
CRNX
KRYS
OUTLOOK RATING
1..100
5757
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
79
Overvalued
PROFIT vs RISK RATING
1..100
6019
SMR RATING
1..100
7667
PRICE GROWTH RATING
1..100
8455
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (79) in the Pharmaceuticals Major industry is in the same range as CRNX (90). This means that KRYS’s stock grew similarly to CRNX’s over the last 12 months.

KRYS's Profit vs Risk Rating (19) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRNX (60). This means that KRYS’s stock grew somewhat faster than CRNX’s over the last 12 months.

KRYS's SMR Rating (67) in the Pharmaceuticals Major industry is in the same range as CRNX (76). This means that KRYS’s stock grew similarly to CRNX’s over the last 12 months.

KRYS's Price Growth Rating (55) in the Pharmaceuticals Major industry is in the same range as CRNX (84). This means that KRYS’s stock grew similarly to CRNX’s over the last 12 months.

KRYS's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as CRNX (100). This means that KRYS’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXKRYS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 8 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 15 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LTCN6.450.18
+2.79%
Grayscale Litecoin Trust (LTC)
AIVI44.25-0.09
-0.20%
WisdomTree Intl Al Enhanced Val ETF
FRA12.03-0.07
-0.58%
Blackrock Floating Rate Income Strategies Fund
XDJL30.69-0.92
-2.90%
Innovator US Equity Acclrtd ETF Jul
XOP108.55-3.38
-3.02%
SPDR® S&P Oil & Gas Explor & Prodtn ETF